■在新西兰,布地奈德/福莫特罗配药逐渐增加,伴随着短效β2-激动剂(SABA)的分配减少,吸入性皮质类固醇(ICSs),和其他ICS/长效β2-激动剂(ICSs/LABAs),发生在2020年新西兰哮喘指南发布后的18个月内,推荐布地奈德/福莫特罗抗炎缓解治疗。
我们的目的是调查新西兰哮喘药物使用和哮喘医院出院的最新趋势。
■对2010年1月至2022年12月期间的新西兰国家吸入器分配数据进行了审查,对象为12岁及以上的患者。布地奈德/福莫特罗的每月配药率,ICSs,其他ICS/LABAs,和SABA通过局部加权散点图平滑图以图形方式显示。在有配药数据的过去6个月(2022年7月至12月)和2019年7月至12月的相应时期之间,比较了哮喘的配药率和出院率。
自2019年以来,布地奈德/福莫特罗的分配量逐渐增加,从2019年7月至12月到2022年7月至12月,青少年和成人的分配量增加了108%。相比之下,其他ICS/LABAs的分发率有所下降,ICSs,和SABA减少3%,18%,5%,分别。在此期间,哮喘的出院率减少了17%.
在新西兰的青少年和成人哮喘患者中,ICS/福莫特罗缓解剂和/或维持治疗已进一步广泛使用。处方实践的变化在时间上与哮喘住院人数的减少有关。
UNASSIGNED: In New Zealand a progressive increase in budesonide/formoterol
dispensing, accompanied by a reduction in
dispensing of short-acting β2-agonists (SABAs), inhaled corticosteroids (ICSs), and other ICS/long-acting β2-agonists (ICSs/LABAs), occurred in the 18-month period following publication of the 2020 New Zealand asthma guidelines, which recommended budesonide/formoterol anti-inflammatory reliever therapy.
UNASSIGNED: Our aim was to investigate more recent trends in asthma medication use and asthma hospital discharges in New Zealand.
UNASSIGNED: New Zealand national
dispensing data for inhalers for the period from January 2010 to December 2022 were reviewed for patients aged 12 years and older. Monthly rates of
dispensing of budesonide/formoterol, ICSs, other ICS/LABAs, and SABAs were displayed graphically by locally weighted scatterplot smoother plots. The rates of
dispensing and hospital discharge for asthma were compared between the past 6 months for which dispensing data were available (July-December 2022) and the corresponding period from July to December 2019.
UNASSIGNED: There has been a progressive increase in dispensing of budesonide/formoterol since 2019, with a 108% increase between the period from July to December 2019 and the period from July to December 2022 in adolescents and adults. In contrast, there was a reduction in rates of dispensing of other ICS/LABAs, ICSs, and SABAs by 3%, 18%, and 5%, respectively. During this period, there was a 17% reduction in hospital discharges for asthma.
UNASSIGNED: There has been a further widespread uptake of ICS/formoterol reliever and/or maintenance therapy in adolescents and adults with asthma in New Zealand. The changes in prescribing practice have been temporally associated with a reduction in hospital admissions for asthma.